drugset / Trial / NCT02053272

A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes

NCT02053272

Phase 2 Completed 207 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to compare the change in glycaemic control in participants with Type 2 diabetes when treated with GWP42004 or placebo as add-on therapy to metformin over a period of 12 weeks. The safety and tolerability of GWP42004 compared with placebo will also be assessed.

Timeline

Start
2014-02
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tetrahydrocannabivarin Small molecule 2 mg
Comparator Tetrahydrocannabivarin Small molecule 5 mg
Comparator Tetrahydrocannabivarin Small molecule 15 mg